Featured Research

from universities, journals, and other organizations

Global progress in preventing newborn deaths, stillbirths hindered by inadequate investment, leadership, measurement, accountability

Date:
May 19, 2014
Source:
The Lancet
Summary:
The clearest picture to date of progress and challenges in improving newborn survival around the world has been presented by researchers, and sets targets that must be achieved by 2030 in order to ensure every newborn has a healthy start. The Series shows that almost all of the 5.5 million newborn and stillborn babies who die every year enter and leave the world without a piece of paper; this lack of registration and official recognition reflects acceptance of these deaths as inevitable, the authors argue.

A major new Series of papers, published today in The Lancet, presents the clearest picture to date of progress and challenges in improving newborn survival around the world, and sets targets that must be achieved by 2030 in order to ensure every newborn has a healthy start.

The research is led by Professor Joy Lawn, at the London School of Hygiene & Tropical Medicine and Save the Children, UK, with Professor Zulfiqar Bhutta at the Hospital for Sick Children, Canada, and the Aga Khan University, Pakistan, in collaboration with more than 54 experts from 28 institutions in 17 countries, and provides the evidence base and foundation for the forthcoming Every Newborn Action Plan [1], an evidence-based roadmap towards care for every woman, and a healthy start for every newborn baby, which will be launched in June 2014.

The Series shows that almost all of the 5.5 million newborn and stillborn babies who die every year enter and leave the world without a piece of paper; this lack of registration and official recognition reflects acceptance of these deaths as inevitable. Preterm babies are less likely to be counted, even in rich countries, especially where they are not expected to survive. The lack of registration is a key reason for slower progress in recent decades for newborn deaths compared to maternal and child mortality reduction -- progress which can, and must, be accelerated if international child mortality targets are to be met.

"Throughout the Series, evidence and experience from some of the most improved, as well as the worst affected, countries shows that newborn and maternal deaths are preventable," says Professor Bhutta. "Our research shows that three million lives can be saved by 2025 if achievable interventions are scaled up to nearly universal coverage, and improving care at the time of birth gives a triple return on investment saving mothers, newborns and stillbirths. Care of small and sick newborns is the next highest impact package, yet this has received little attention up to now, despite extremely cost effective solutions such as antenatal steroids and kangaroo mother care."

Professor Lawn adds, "So far investment targeted to newborn health has been minuscule -- nearly half (44%) of all deaths in children under five are in the first month of life, yet only 4% of donor funding to child health even mentions the word 'newborn'. Another critical issue is the need for more midwives and nurses with skills to look after women in labour and small and sick newborns. We now know what needs to be done differently -- and the Series outlines bold, but achievable, targets for reducing newborn deaths and stillbirths. The forthcoming Every Newborn Action Plan will build on these targets and provide momentum in many countries for accelerated action."

The Every Newborn series can be accessed at: http://www.thelancet.com/series/everynewborn


Story Source:

The above story is based on materials provided by The Lancet. Note: Materials may be edited for content and length.


Cite This Page:

The Lancet. "Global progress in preventing newborn deaths, stillbirths hindered by inadequate investment, leadership, measurement, accountability." ScienceDaily. ScienceDaily, 19 May 2014. <www.sciencedaily.com/releases/2014/05/140519184617.htm>.
The Lancet. (2014, May 19). Global progress in preventing newborn deaths, stillbirths hindered by inadequate investment, leadership, measurement, accountability. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/05/140519184617.htm
The Lancet. "Global progress in preventing newborn deaths, stillbirths hindered by inadequate investment, leadership, measurement, accountability." ScienceDaily. www.sciencedaily.com/releases/2014/05/140519184617.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins